Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

> Total other

income, net 1,299,076 516,287 5,978,564 2,197,821

Loss before tax

provision (20,748,597) (11,890,926) (74,059,811) (63,510,619)

Income tax

provision (191) 549 9,879 549

Net loss $ (20,748,406) $ (11,891,475) $ (74,069,690) $ (63,511,168)

Basic and

diluted net

loss per

common share $ (0.78) $ (0.54) $ (2.81) $ (3.97)

Shares used in

calculation of

basic and

diluted

net loss

per common

share 26,644,540 21,932,730 26,360,177 16,001,815

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

December 31, 2007 December 31, 2006

ASSETS

Current assets:

Cash and cash equivalents $41,929,533 $30,928,895

Marketable securities 43,243,960 941,981

Prepaid expenses, deposits and

other current assets 1,781,881 1,949,466

Total current assets 86,955,374 33,820,342

Marketable securities, long-term 7,979,331 -

Property and equipment, net 1,345,845 1,859,704

Deposits 150,000 150,000

Restricted cash 430,230 430,230

Total assets $96,860,780 $36,260,276

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $2,988,069 $2,783,249

Accrued expenses 9,789,738 6,322,808


'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Controlled Substance ... Alliance, which helps companies check the legal requirements around ... expand to China. , As their international operations ... globally adopting software solutions built as a result of ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the third quarter ended September 30,2008., ... available to common shareholders for the three months,ended ...
... (Nasdaq: PRXL ), a leading global biopharmaceutical ... the first to conduct a,Chinese bridging study outside ... bridging studies, which are conducted in early clinical ... gather,relevant ethnic data in the U.S., and save ...
... US In ... Locations Other Than Switzerland, BETHESDA, Md., Nov. 6 ... NWBT), today,announced that it has obtained US$1.65 million in funding ... Capital Group SPC,Ltd ("SDS") and a group of private investors ...
Cached Biology Technology:Advanced Life Sciences Announces Third Quarter 2008 Financial Results 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 3Advanced Life Sciences Announces Third Quarter 2008 Financial Results 4Advanced Life Sciences Announces Third Quarter 2008 Financial Results 5Advanced Life Sciences Announces Third Quarter 2008 Financial Results 6Advanced Life Sciences Announces Third Quarter 2008 Financial Results 7Advanced Life Sciences Announces Third Quarter 2008 Financial Results 8Advanced Life Sciences Announces Third Quarter 2008 Financial Results 9Advanced Life Sciences Announces Third Quarter 2008 Financial Results 10Advanced Life Sciences Announces Third Quarter 2008 Financial Results 11PAREXEL Expands Pioneering Asian Ethnobridging Expertise 2PAREXEL Expands Pioneering Asian Ethnobridging Expertise 3PAREXEL Expands Pioneering Asian Ethnobridging Expertise 4PAREXEL Expands Pioneering Asian Ethnobridging Expertise 5Northwest Secures US$1.65 Million Debt Financing 2Northwest Secures US$1.65 Million Debt Financing 3Northwest Secures US$1.65 Million Debt Financing 4
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... a calcium carbonate crystal, a simple mollusk may have evolved ... Speiser, a postdoctoral fellow in the Department of Ecology Evolution ... he collected in the Florida Keys. His research of their ... in a study published today by Current Biology . ...
... of couples struggling with infertility is on the rise, and ... fertilization (IVF), to get pregnant. Although IVF can be ... (i.e., twins or triplets), which are often caused by transferring ... to be born prematurely, and, as a result, many have ...
... DALLAS April 14, 2011 A natural hormone ... fibrosis, UT Southwestern Medical Center researchers have demonstrated. Scientists ... in mice that the anti-aging hormone Klotho suppressed both renal ... and the spread of cancer. The findings are available online ...
Cached Biology News:Eyes of rock let chitons see predators 2New study finds stronger regulations of in vitro fertilization may save lives 2Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... Acridinium NHS ester can ... and nucleic acids. The covalently ... produce chemiluminescence in the presence ... ester-labeled proteins can be used ...
Biology Products: